Towards definition of the global biotechnology value chain using cases from Australian biotechnology SMEs

Kapeleris, John, Hine, Damien and Barnard, Ross (2004) Towards definition of the global biotechnology value chain using cases from Australian biotechnology SMEs. International Journal of Globalisation and Small Business, 1 1: 79-91. doi:10.1504/IJGSB.2004.005619


Author Kapeleris, John
Hine, Damien
Barnard, Ross
Title Towards definition of the global biotechnology value chain using cases from Australian biotechnology SMEs
Journal name International Journal of Globalisation and Small Business   Check publisher's open access policy
ISSN 1479-3059
Publication date 2004
Sub-type Article (original research)
DOI 10.1504/IJGSB.2004.005619
Volume 1
Issue 1
Start page 79
End page 91
Total pages 13
Editor S. Royer
Place of publication Bucks, UK
Publisher Inderscience Enterprises
Collection year 2004
Language eng
Subject C1
350211 Innovation and Technology Management
670400 Human Pharmaceutical Products
Abstract The generic pharmaceutical value chain model has been employed to describe both the global pharmaceutical and biotechnology industries till now. This research investigates the organisational value chain in Australian biotechnology companies in order to assess the appropriateness of the pharmaceutical value chain to small-and medium-sized biotechnology companies. The main theme of the research is: Can a generic model of the organisational value chain be defined for the biotechnology industry? Emanating from the literature, two research propositions were developed. RP1: there are eight major definable elements/activities of the organisational value chain for the biotechnology industry. RP2: Coverage of the elements in the biotechnology value chain ranges from focused to broad. A multiple case study methodology was used to explore these propositions. To develop a number of case studies, data was collected from senior managers of small and medium Australian biotechnology companies using an interview instrument, as well as from publicly available documentation and through observation. The results were analysed using cross-case comparisons. The results showed that an aggregation of the value chains of each organisation can be reduced to these eight definable elements that constitute the biotechnology value chain: basic research, applied research, development, verification and validation, prototype development, clinical trials, manufacturing and marketing. However, the findings also indicate that these major elements of the value chain need to be further reduced into sub-activities or sub-tasks to cater for the unique differences between biotechnology companies. Generally, the findings were consistent with the literature. However, a wider sampling, including international biotechnology organisations should be studied. The major contribution of this research is in the development of a value chain model, including general sub-tasks, for the Australian biotechnology industry.
Keyword Australia
Global biotechnology value chain
SMEs
Global value chain
Innovation
Small-to-medium sized enterprises
Small business.
Q-Index Code C1

 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 03:23:44 EST